Population pharmacokinetic study of teicoplanin in severely neutropenic patients

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1242-1247

  Lortholary, Olivier ^a   Tod, Michel ^a   Rizzo, Nathalie ^a   Padoin, Christophe ^a   Biard, Olivier ^a   Casassus, Philippe ^a   Guillevin, Loic ^a   Petitjean, Olivier ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; PIPERACILLIN; TEICOPLANIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; MALE; NEUTROPENIA; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION;

EID: 0029995354     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1242     Document Type: Article

References (28)

1. Bodey, G. P. 1989. Evolution of antibiotic therapy for infection in neutropenic patients: studies at MD Anderson Hospital Rev. Infect Dis. 11:1582-1590.
2. Brogden, R. N., and D. H, Peters. 1994. Teicoplanin: a reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:823-854.
3. Brown, A. E. 1984. Neutropema. fever and infection. Am. J. Med. 76:421-428.
4. 14C-teicoplanin in healthy volunteers. Internal report. Merrell-Dow, Levallois, France.
5. Carver, P. L., C. H. Nightingale, R. Quintiliani, K. Sweeney, R. C. Stevens, and E. Madezo. 1989. Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers. Antimicrob. Agents Chemother. 33:82-86
6. Chambers, H. F., and S. Kennedy. 1990 Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother. 34:510-514.
7. Chang, D., L. Liem, and M. Malogolowkin. 1994. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Pediatr. Infect. Dis. J. 13:969-974.
8. Cockroft, D. W., and M. H. Gault. 1976 Prediction of creatinine clearance from serum creatinine, Nephron 16:31-41
9. Cremieux, A. C., B. Maziere, J. M. Vallois, M. Ottaviani, A. Azancot, H. Raffoul, A. Bouvet, J. J. Pocidalo, and C. Carbon. 1989. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J. Infect Dis. 159:938-944.
10. Del Mar Fernandez de Gatta, M., I. Fruns, J. M. Hernandez, D. Caballero, J. F. San Miguel, J. Martinez Lanao, and A. Dominguez-Gil Hurle. 1993. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 6:963-966.
11. Gomeni, R., G. Pineau, and F. Mentré, 1994. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. Anticancer Res 14:2321-2326.
12. Jehl, F., H. Monteil, and A. Tarral. 1982. HPLC quantitation of six main components of teicoplanin in biological fluids. J. Antimicrob. Chemother. 21(Suppl. A):53-59.
13. Kureishi, A., P. J. Jewesson, K. H. Bartlett, C. D. Cole, and A. W. Chow. 1990. Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients. Antimicrob Agents Chemother 34:1642-1647.
14. Kureishi, A., P. J. Jewesson, M. Rubinger, C. D. Cole, D. E. Reece, G. L. Phillips, J. A. Smith, and A. W. Chow. 1991. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect of cyclosporin A-associated nephrotoxicity. Antimicrob. Agents Chemother. 35:2246-2252.
15. Leport, C., C. Perronne, P. Massip, P. Canton, P. Leclercq, E. Bernard, P. Lutun, J. J. Garaud, and J. L. Vildé. 1989. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrob. Agents Chemother. 33:871-876.
16. Ludden, T. M., S. L. Beal, and L. B. Sheiner. 1994. Comparison of the Akaike information criterion, the Schwartz criterion and the F test as guides to model selection J. Pharmacokinet Biopharm. 22:431-445
17. Menichetti, F., P. Martino, G. Bucaneve, G. Gentile, D. D. Antonio, V. Liso, P. Ricci, A. M. Nosari, M. Buelli, M. Carotenuto, G. Fasola, P. Jacopino, M. Montillo, G. Barbabietola, C. Girmenia, A. Del Favero, and the Gimema Infection Program. 1994 Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile neutropenic patients with hematologie malignancies. Antimicrob. Agents Chemother 38:2041-2046.
18. Mentré, F., and R. Gomeni. 1995. A two-step iterative algorithm for estimation in non-linear mixed-effect models with an evaluation in population pharmacokinetics. J. Biopharm. Stat. 5:141-158.
19. Press, W. H., S. A. Teukolsky, W. T. Vetterling, and B. P. Flannery. 1992. Numerical recipes in C. the art of scientific computing. 2nd ed. Cambridge University Press, Cambridge.
20. Rowland, M. 1990. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 18:184-209.
21. Rubin, M., J. W. Hathorn, D. Marshall, J. Gress, S. M. Steinberg, and P. A. Pizzo. 1988. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann. Intern Med. 108:30-35.
22. Schumitzky, A. 1991. Non parametric EM algorithms for estimating prior distributions. Appl. Math. Comput. 45:143-157.
23. Smithers, J. A., H. K. Kulmala, G. A. Thompson, K. K. Anthony, E. W. Lewis, S. J. Ruberg, M. T. Kenny, J. K. Dulworth, and M. A. Brackman. 1992. Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 mg/kg of body weight to healthy volunteers. Antimicrob. Agents Chemother. 36:115-120.
24. Steimer, J. L., A. Mallet, and F. Mentré. 1985. Estimating inter-individual pharmacokinetic variability, p. 65-111. In M. Rowland, L. B. Skeiner, and J. L. Steiner (ed), Variability in drug therapy: description, estimation and control Raven Press, New York.
25. Torney, H. L., F. J. Balistreri, M. T. Kenny, and W. D. Chang. 1991. Comparative therapeutic efficacy of teicoplanin and vancomycin in normal and neutropenic mice infected with Staphylococcus haemolyticus. J. Antimicrob. Chemother. 28:261-269.
26. Verbist, L., B. Tjandramaga, B. Hendrickx. A. Van Hecken, and P. Van Mell. 1984. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob. Agents Chemother. 26:881-886.
27. Wilson, A. P. R., R. N. Grüneberg, and II. Neu. 1994. A critical review of the dosage of teicoplanin in Europe and the USA. Int J. Antimicrob. Agents 4(Suppl. 1):S1-S30.
28. Zeitany. R. G., N. S. El Saghir, R. Cheruppolil, R. Santosh-Kumar, and M. A. Sigmon. 1990. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob. Agents Chemother. 34:702-708.